KOD: Zenkuda’s BLA, KSI-101’s PEAK 1 readout and accelerating KSI-501 trials define the near-term milestones

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Zenkuda’s DAYBREAK results supported six-month dosing for many patients, and its three-indication BLA was targeted for year-end 2026. KSI-101’s PEAK 1 readout was expected before Christmas, while KSI-501’s DME Phase III program was accelerating.

Based on

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.